Latest News - Leo

Wednesday, January 09, 2019

LEO Pharma Focuses on Translational Medicine, Appoints Dr. Adam B. Raff as Director & Medical Advisor

LEO Pharma has appointed Adam B. Raff, MD, PhD as Director and Medical Advisor in Translational Medicine, effective January 28. Dr. Raff’s primary objective will be to support LEO Pharma’s…

Read the full story

Tuesday, November 20, 2018

LEO, PellePharm Form Collaboration Focused on Innovation

A new strategic development and commercialization collaboration between LEO Pharma and PellePharm is intended to address unmet medical needs across various skin diseases with no approved treatments, t…

Read the full story

Tuesday, September 04, 2018

JW Pharmaceutical Signs Global Out-licensing Agreement for Atopic Dermatitis Drug Candidate with LEO Pharma

JW Pharmaceutical and LEO Pharma A/S have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma will gain the exclusive rights to …

Read the full story

Tuesday, July 31, 2018

LEO Pharma to Acquire Bayer Prescription Dermatology Business

LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription treatments for acne, fung…

Read the full story

Tuesday, June 26, 2018

LEO Pharma and Advancing Innovation in Dermatology Partner to Help Finance Accelerator Fund

LEO Pharma and its Boston-based R&D innovation unit LEO Science & Tech Hub, and Advancing Innovation in Dermatology (AID) will each contribute $500,000 into the recently created Advancing Inno…

Read the full story

Thursday, July 20, 2017

LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasis

The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the Eur…

Read the full story

Thursday, May 04, 2017

LEO Pharma U.S. Welcomes Judit H. Nyirady as Vice President of Medical Strategy & Scientific Affairs

Judit H. Nyirady, MD, MBA, is the new Vice President of Medical Strategy & Scientific Affairs at LEO Pharma Inc. In this role, she will be responsible for the medical and scientific affairs str…

Read the full story

Friday, July 01, 2016

Valeant Terminates European Licensing Rights for Brodalumab

Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patient…

Read the full story

Tuesday, January 19, 2016

Psoriasis Treatment Update: Rx Enstilar® Is Here

Enstilar®, the recently approved plaque psoriasis foam, is now available in pharmacies by prescription. Manufactured by LEO Pharma, Inc.,  Enstilar® is a once-daily, alcohol-free …

Read the full story

Wednesday, November 11, 2015

LEO Pharma to Acquire Global Dermatology Portfolio from Astellas

LEO Pharma A/S and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma f…

Read the full story

Monday, October 19, 2015

LEO Pharma Inc. Announces FDA Approval of Enstilar Foam for Plaque Psoriasis

The FDA approved LEO Pharma Inc’s Enstilar for the topical treatment of plaque psoriasis in adults 18 years of age and older. Enstilar is a once-daily, alcohol free foam formulation in a pres…

Read the full story

Monday, July 06, 2015

LEO Pharma Inc. Announces New Vice President of Sales

Mitchell Johnson has joined the LEO U.S. Region as Vice President of Sales. "Mitch is a welcomed addition to our team. He is an energetic sales leader and strategist with proven results in the ph…

Read the full story

Wednesday, June 10, 2015

Investigational Foam May Offer Itch Relief for Psoriasis Patients

An investigational aerosol foam may provide rapid itch relief as well as improvements in itch-related sleep loss for patients with psoriasis, according to new data presented at the recent World Congre…

Read the full story

Friday, May 22, 2015

arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma entered into…

Read the full story

Tuesday, January 06, 2015

LEO Pharma Submits NDA for Aerosol Foam for Psoriasis to FDA

LEO Pharma has submitted a New Drug Application to FDA for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the treatment of psoriasis vulgaris. The novel aerosol foam formul…

Read the full story